Last reviewed · How we verify
bevacizumab + triamcinolone acetonide
Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), while triamcinolone acetonide is a corticosteroid that reduces inflammation.
Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), while triamcinolone acetonide is a corticosteroid that reduces inflammation. Used for Metastatic colorectal cancer, Nonsquamous non-small cell lung cancer.
At a glance
| Generic name | bevacizumab + triamcinolone acetonide |
|---|---|
| Sponsor | Shahid Beheshti University of Medical Sciences |
| Drug class | Angiogenesis inhibitor, Corticosteroid |
| Target | VEGF-A |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Bevacizumab works by binding to VEGF-A, preventing it from interacting with its receptor and thereby inhibiting angiogenesis. Triamcinolone acetonide, on the other hand, has anti-inflammatory properties that help to reduce swelling and alleviate symptoms.
Approved indications
- Metastatic colorectal cancer
- Nonsquamous non-small cell lung cancer
Common side effects
- Hypertension
- Proteinuria
- Headache
- Nausea
- Diarrhea
Key clinical trials
- Bevacizumab Versus Triamcinolone Acetonide for the Treatment of Keloids. (PHASE4)
- Comparison of Intravitreal Bevacizumab Injection with Combination of Suprachoroidal Triamcinolone Acetonide Along with Intravitreal Bevacizumab Injection in the Treatment of Diabetic Macular Edema in Pseudophakic Patients (PHASE4)
- IVB for Post-vitrectomy Hemorrhage in Diabetic Eyes (NA)
- Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization (PHASE2, PHASE3)
- Vitrectomy Without Internal Limiting Membrane Removal in the Treatment of Diffuse Diabetic Macular Edema: a Comparative Kenalog Vs Bevacizumab Intravitreal Injection Vs Control Study (PHASE3)
- Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO (PHASE4)
- Comparison of Intravitreal Anti-VEGF Versus Combination Therapy in Central Retinal Vein Occlusion (NA)
- Bevacizumabe or Triamcinolone for Persistent Diabetic Macular Edema (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: